Multivalent IgM scaffold enhances the therapeutic potential of variant-agnostic ACE2 decoys against SARS-CoV-2

References

• World Health Organization. WHO coronavirus (COVID-19) dashboard; 2023 May 19. https://covid19.who.int/.
   Google Scholar
• Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, Muecksch F, Rutkowska M, Hoffmann HH, Michailidis E, et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 2020;9. doi:10.7554/eLife.61312. PMID: 33112236.
   PubMed Web of Science ®Google Scholar
• Andreano E, Piccini G, Licastro D, Casalino L, Johnson NV, Paciello I, Dal Monego S, Pantano E, Manganaro N, Manenti A, et al. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma. Proc Natl Acad Sci U S A. 2021;118(36):118. doi:10.1073/pnas.2103154118. PMID: 34417349.
   Web of Science ®Google Scholar
• McCarthy KR, Rennick LJ, Nambulli S, Robinson-McCarthy LR, Bain WG, Haidar G, Duprex WP. Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. Science. 2021;371(6534):1139–13. doi:10.1126/science.abf6950. PMID: 33536258.
   PubMed Web of Science ®Google Scholar
• Yamasoba D, Kosugi Y, Kimura I, Fujita S, Uriu K, Ito J, Sato K, Genotype to Phenotype Japan C. Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies. Lancet Infect Dis. 2022;22(7):942–43. doi:10.1016/S1473-3099(22)00365-6. PMID: 35690075.
   PubMed Web of Science ®Google Scholar
• Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L, Du S, Wang J, Li Q, Chen X, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022;608(7923):593–602. doi:10.1038/s41586-022-04980-y. PMID: 35714668.
   PubMed Web of Science ®Google Scholar
• Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;5(4):562–69. doi:10.1038/s41564-020-0688-y. PMID: 32094589.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–80 e278. doi:10.1016/j.cell.2020.02.052. PMID: 32142651.
   PubMed Web of Science ®Google Scholar
• Greaney AJ, Starr TN, Barnes CO, Weisblum Y, Schmidt F, Caskey M, Gaebler C, Cho A, Agudelo M, Finkin S, et al. Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. Nat Commun. 2021;12(1):4196. doi:10.1038/s41467-021-24435-8. PMID: 34234131.
   PubMed Web of Science ®Google Scholar
• Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, Agudelo M, Barnes CO, Gazumyan A, Finkin S, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020;584(7821):437–42. doi:10.1038/s41586-020-2456-9. PMID: 32555388.
   PubMed Web of Science ®Google Scholar
• Piccoli L, Park YJ, Tortorici MA, Czudnochowski N, Walls AC, Beltramello M, Silacci-Fregni C, Pinto D, Rosen LE, Bowen JE, et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell. 2020;183(4):1024–42 e1021. doi:10.1016/j.cell.2020.09.037. PMID: 32991844.
   PubMed Web of Science ®Google Scholar
• Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY, Bloom JD. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host & Microbe. 2021;29(3):463–76 e466. doi:10.1016/j.chom.2021.02.003. PMID: 33592168.
   PubMed Web of Science ®Google Scholar
• Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2021;21(2):73–82. doi:10.1038/s41577-020-00480-0. PMID: 33340022.
   PubMed Web of Science ®Google Scholar
• Sternberg A, Naujokat C. Structural features of coronavirus SARS-CoV-2 spike protein: targets for vaccination. Life Sci. 2020;257:118056. doi:10.1016/j.lfs.2020.118056. PMID: 32645344.
   PubMed Web of Science ®Google Scholar
• Corti D, Purcell LA, Snell G, Veesler D. Tackling COVID-19 with neutralizing monoclonal antibodies. Cell. 2021;184(17):4593–95. doi:10.1016/j.cell.2021.07.027. PMID: 34416148.
   PubMed Web of Science ®Google Scholar
• Cameroni E, Bowen JE, Rosen LE, Saliba C, Zepeda SK, Culap K, Pinto D, VanBlargan LA, De Marco A, di Iulio J, et al. Broadly neutralizing antibodies overcome SARS-CoV-2 omicron antigenic shift. Nature. 2022;602(7898):664–70. doi:10.1038/s41586-021-04386-2. PMID: 35016195.
   PubMed Web of Science ®Google Scholar
• Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, Ludden C, Reeve R, Rambaut A, Consortium CG, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19(7):409–24. doi:10.1038/s41579-021-00573-0. PMID: 34075212.
   PubMed Web of Science ®Google Scholar
• Starr TN, Greaney AJ, Addetia A, Hannon WW, Choudhary MC, Dingens AS, Li JZ, Bloom JD. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Sci. 2021;371(6531):850–54. doi:10.1126/science.abf9302. PMID: 33495308.
   PubMed Web of Science ®Google Scholar
• Liu Z, VanBlargan LA, Bloyet LM, Rothlauf PW, Chen RE, Stumpf S, Zhao H, Errico JM, Theel ES, Liebeskind MJ, et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host & Microbe. 2021;29(3):477–88 e474. doi:10.1016/j.chom.2021.01.014. PMID: 33535027.
   PubMed Web of Science ®Google Scholar
• Li Q, Wu J, Nie J, Zhang L, Hao H, Liu S, Zhao C, Zhang Q, Liu H, Nie L, et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell. 2020;182(5):1284–94 e1289. doi:10.1016/j.cell.2020.07.012. PMID: 32730807.
   PubMed Web of Science ®Google Scholar
• VanBlargan LA, Errico JM, Halfmann PJ, Zost SJ, Crowe JE Jr., Purcell LA, Kawaoka Y, Corti D, Fremont DH, Diamond MS. An infectious SARS-CoV-2 B.1.1.529 omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med. 2022;28(3):490–95. doi:10.1038/s41591-021-01678-y. PMID: 35046573.
   PubMed Web of Science ®Google Scholar
• Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593(7857):130–35. doi:10.1038/s41586-021-03398-2. PMID: 33684923.
   PubMed Web of Science ®Google Scholar
• McCallum M, Bassi J, De Marco A, Chen A, Walls AC, Di Iulio J, Tortorici MA, Navarro MJ, Silacci-Fregni C, Saliba C, et al. SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. Sci. 2021;373(6555):648–54. doi:10.1126/science.abi7994. PMID: 34210893.
   PubMed Web of Science ®Google Scholar
• Chen RE, Winkler ES, Case JB, Aziati ID, Bricker TL, Joshi A, Darling TL, Ying B, Errico JM, Shrihari S, et al. In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. Nature. 2021;596(7870):103–08. doi:10.1038/s41586-021-03720-y. PMID: 34153975.
   PubMed Web of Science ®Google Scholar
• Wang P, Casner RG, Nair MS, Wang M, Yu J, Cerutti G, Liu L, Kwong PD, Huang Y, Shapiro L, et al. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. Cell Host & Microbe. 2021;29(5):747–51 e744. doi:10.1016/j.chom.2021.04.007. PMID: 33887205.
   PubMed Web of Science ®Google Scholar
• Morris DH, Gostic KM, Pompei S, Bedford T, Luksza M, Neher RA, Grenfell BT, Lassig M, McCauley JW. Predictive modeling of influenza shows the promise of applied evolutionary biology. Trends Microbiol. 2018;26(2):102–18. doi:10.1016/j.tim.2017.09.004. PMID: 29097090.
   PubMed Web of Science ®Google Scholar
• Sun Y, Lin W, Dong W, Xu J. Origin and evolutionary analysis of the SARS-CoV-2 omicron variant. J Biosaf Biosecur. 2022;4(1):33–37. doi:10.1016/j.jobb.2021.12.001. PMID: 35005525.
   PubMedGoogle Scholar
• Alfaleh MA, Zawawi A, Al-Amri SS, Hashem AM. David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors. MAbs. 2022;14(1):2057832. doi:10.1080/19420862.2022.2057832.
   PubMed Web of Science ®Google Scholar
• Lei C, Qian K, Li T, Zhang S, Fu W, Ding M, Hu S. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. Nat Commun. 2020;11(1):2070. doi:10.1038/s41467-020-16048-4. PMID: 32332765.
   PubMed Web of Science ®Google Scholar
• Tanaka S, Nelson G, Olson CA, Buzko O, Higashide W, Shin A, Gonzalez M, Taft J, Patel R, Buta S, et al. An ACE2 triple decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants. null. 2021;11:12740. doi:10.1038/s41598-021-91809-9.
   Google Scholar
• Guo L, Bi W, Wang X, Xu W, Yan R, Zhang Y, Zhao K, Li Y, Zhang M, Cai X, et al. Engineered trimeric ACE2 binds viral spike protein and locks it in “three-up” conformation to potently inhibit SARS-CoV-2 infection. Cell Res. 2021;31:98–100. doi:10.1038/s41422-020-00438-w. PMID: 33177651.
   PubMed Web of Science ®Google Scholar
• Miller A, Leach A, Thomas J, McAndrew C, Bentley E, Mattiuzzo G, John L, Mirazimi A, Harris G, Gamage N, et al. A super-potent tetramerized ACE2 protein displays enhanced neutralization of SARS-CoV-2 virus infection. null. 2021;11:10617. doi:10.1038/s41598-021-89957-z. PMID: 34012108.
   Google Scholar
• Hunt AC, Case JB, Park YJ, Cao L, Wu K, Walls AC, Liu Z, Bowen JE, Yeh HW, Saini S, et al. Multivalent designed proteins protect against SARS-CoV-2 variants of concern. bioRxiv. 2021. doi:10.1101/2021.07.07.451375. PMID: 34268509.
   PubMedGoogle Scholar
• Zhang L, Dutta S, Xiong S, Chan M, Chan KK, Fan TM, Bailey KL, Lindeblad M, Cooper LM, Rong L, et al. Engineered ACE2 decoy mitigates lung injury and death induced by SARS-CoV-2 variants. Nat Chem Biol. 2022. doi:10.1038/s41589-021-00965-6. PMID: 35046611.
   Web of Science ®Google Scholar
• Chan KK, Dorosky D, Sharma P, Abbasi SA, Dye JM, Kranz DM, Herbert AS, Procko E. Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. Science. 2020;369:1261–65. doi:10.1126/science.abc0870. PMID: 32753553.
   PubMed Web of Science ®Google Scholar
• Cao L, Goreshnik I, Coventry B, Case JB, Miller L, Kozodoy L, Chen RE, Carter L, Walls AC, Park YJ, et al. De Novo design of picomolar SARS-CoV-2 miniprotein inhibitors. Science. 2020;370:426–31. doi:10.1126/science.abd9909. PMID: 32907861.
   PubMed Web of Science ®Google Scholar
• Xiao T, Lu J, Zhang J, Johnson RI, McKay LGA, Storm N, Lavine CL, Peng H, Cai Y, Rits-Volloch S, et al. A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent. Nature Struct Molecul Biol. 2021;28:202–09. doi:10.1038/s41594-020-00549-3.
   PubMed Web of Science ®Google Scholar
• Linsky TW, Vergara R, Codina N, Nelson JW, Walker MJ, Su W, Barnes CO, Hsiang TY, Esser-Nobis K, Yu K, et al. De Novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2. Sci. 2020;370:1208–14. doi:10.1126/science.abe0075. PMID: 33154107.
   PubMed Web of Science ®Google Scholar
• Patino-Galindo JA, Filip I, Chowdhury R, Maranas CD, Sorger PK, AlQuraishi M, Rabadan R. Recombination and lineage-specific mutations linked to the emergence of SARS-CoV-2. Genome Med. 2021;13:124. doi:10.1186/s13073-021-00943-6. PMID: 34362430.
   PubMed Web of Science ®Google Scholar
• Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A, Li F. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581:221–24. doi:10.1038/s41586-020-2179-y. PMID: 32225175.
   PubMed Web of Science ®Google Scholar
• Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS. Cryo-EM structure of the 2019-nCov spike in the prefusion conformation. Sci. 2020;367:1260–63. doi:10.1126/science.abb2507. PMID: 32075877.
   PubMed Web of Science ®Google Scholar
• Gutgsell AR, Gunnarsson A, Forssen P, Gordon E, Fornstedt T, Geschwindner S. Biosensor-enabled deconvolution of the avidity-induced affinity enhancement for the SARS-CoV-2 spike protein and ACE2 interaction. Anal Chem. 2022;94:1187–94. doi:10.1021/acs.analchem.1c04372. PMID: 34964599.
   PubMed Web of Science ®Google Scholar
• Imai M, Iwatsuki-Horimoto K, Hatta M, Loeber S, Halfmann PJ, Nakajima N, Watanabe T, Ujie M, Takahashi K, Ito M, et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc Natl Acad Sci U S A. 2020;117:16587–95. doi:10.1073/pnas.2009799117. PMID: 32571934.
   PubMed Web of Science ®Google Scholar
• Tamming LA, Duque D, Tran A, Zhang W, Pfeifle A, Laryea E, Wu J, Raman SNT, Gravel C, Russell MS, et al. DNA based vaccine expressing SARS-CoV-2 spike-CD40L fusion protein confers protection against challenge in a Syrian hamster model. Front Immunol. 2021;12:785349. doi:10.3389/fimmu.2021.785349. PMID: 35095861.
   PubMed Web of Science ®Google Scholar
• Mulka KR, Beck SE, Solis CV, Johanson AL, Queen SE, McCarron ME, Richardson MR, Zhou R, Marinho P, Jedlicka A, et al. Progression and resolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in golden Syrian hamsters. Am J Pathol. 2022;192:195–207. doi:10.1016/j.ajpath.2021.10.009. PMID: 34767812.
   PubMed Web of Science ®Google Scholar
• Gruber AD, Osterrieder N, Bertzbach LD, Vladimirova D, Greuel S, Ihlow J, Horst D, Trimpert J, Dietert K. Standardization of reporting criteria for lung pathology in SARS-CoV-2-infected hamsters: what matters? Am J Respir Cell Mol Biol. 2020;63:856–59. doi:10.1165/rcmb.2020-0280LE. PMID: 32897757.
   PubMed Web of Science ®Google Scholar
• Svilenov HL, Bester R, Sacherl J, Absmeier R, Peters C, Protzer U, Brockmeyer C, Buchner J. Multimeric ACE2-IgM fusions as broadly active antivirals that potently neutralize SARS-CoV-2 variants. Commun Biol. 2022;5:1237. doi:10.1038/s42003-022-04193-z. PMID: 36371561.
   PubMed Web of Science ®Google Scholar
• Campbell M. A conversation with Professor Josef Penninger on the journey to a COVID-19 therapeutic; 2020. https://www.technologynetworks.com/proteomics/blog/a-conversation-with-professor-josef-penninger-on-the-journey-to-a-covid-19-therapeutic-340785.
   Google Scholar
• Monteil V, Kwon H, Prado P, Hagelkruys A, Wimmer RA, Stahl M, Leopoldi A, Garreta E, Hurtado Del Pozo C, Prosper F, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181:905–13 e907. doi:10.1016/j.cell.2020.04.004. PMID: 32333836.
   PubMed Web of Science ®Google Scholar
• Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875–79. doi:10.1038/nm1267. PMID: 16007097.
   PubMed Web of Science ®Google Scholar
• Lovren F, Pan Y, Quan A, Teoh H, Wang G, Shukla PC, Levitt KS, Oudit GY, Al-Omran M, Stewart DJ, et al. Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am J Physiol Heart Circ Physiol. 2008;295:H1377–1384. doi:10.1152/ajpheart.00331.2008. PMID: 18660448.
   PubMed Web of Science ®Google Scholar
• Khan A, Benthin C, Zeno B, Albertson TE, Boyd J, Christie JD, Hall R, Poirier G, Ronco JJ, Tidswell M, et al. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care. 2017;21:234. doi:10.1186/s13054-017-1823-x. PMID: 28877748.
   PubMed Web of Science ®Google Scholar
• Zoufaly A, Poglitsch M, Aberle JH, Hoepler W, Seitz T, Traugott M, Grieb A, Pawelka E, Laferl H, Wenisch C, et al. Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir Med. 2020;8:1154–58. doi:10.1016/S2213-2600(20)30418-5. PMID: 33131609.
   PubMed Web of Science ®Google Scholar
• Iwasaki A. Exploiting mucosal immunity for antiviral vaccines. Annu Rev Immunol. 2016;34:575–608. doi:10.1146/annurev-immunol-032414-112315. PMID: 27168245.
   PubMed Web of Science ®Google Scholar
• Hou YJ, Okuda K, Edwards CE, Martinez DR, Asakura T, Dinnon KH, Kato T, Lee RE, Yount BL, Mascenik TM, et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell. 2020;182:429–46 e414. doi:10.1016/j.cell.2020.05.042. PMID: 32526206.
   PubMed Web of Science ®Google Scholar
• Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323:1843–44. doi:10.1001/jama.2020.3786. PMID: 32159775.
   PubMed Web of Science ®Google Scholar
• Parray HA, Shukla S, Perween R, Khatri R, Shrivastava T, Singh V, Murugavelu P, Ahmed S, Samal S, Sharma C, et al. Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections. Appl Microbiol Biotechnol. 2021;105:6315–32. doi:10.1007/s00253-021-11488-4. PMID: 34423407.
   PubMed Web of Science ®Google Scholar
• Ku Z, Xie X, Hinton PR, Liu X, Ye X, Muruato AE, Ng DC, Biswas S, Zou J, Liu Y, et al. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. Nature. 2021;595:718–23. doi:10.1038/s41586-021-03673-2. PMID: 34082438.
   PubMed Web of Science ®Google Scholar
• Halwe S, Kupke A, Vanshylla K, Liberta F, Gruell H, Zehner M, Rohde C, Krahling V, Gellhorn Serra M, Kreer C, et al. Intranasal administration of a monoclonal neutralizing antibody protects mice against SARS-CoV-2 infection. Viruses. 2021;13. doi:10.3390/v13081498. PMID: 34452363.
   Web of Science ®Google Scholar
• Fu YM, Singh A, Lim R, Ledesma A, Lee D, Rivero-Nava L, Ko J, Rivera I, Sattler RA, Manning JT, et al. Protective effects of STI-2020 antibody delivered post-infection by the intranasal or intravenous route in a Syrian golden hamster COVID-19 model. bioRxiv. 2020. doi:10.1101/2020.10.28.359836.
   Google Scholar
• Urano E, Itoh Y, Suzuki T, Sasaki T, Kishikawa JI, Akamatsu K, Higuchi Y, Sakai Y, Okamura T, Mitoma S, et al. An engineered ACE2 decoy broadly neutralizes omicron subvariants and shows therapeutic effect in SARS-CoV-2-infected cynomolgus macaques. bioRxiv. 2023. doi:10.1101/2022.12.29.522275.
   PubMedGoogle Scholar
• Makela AR, Ugurlu H, Hannula L, Kant R, Salminen P, Fagerlund R, Maki S, Haveri A, Strandin T, Kareinen L, et al. Intranasal trimeric sherpa body inhibits SARS-CoV-2 including recent immunoevasive omicron subvariants. Nat Commun. 2023;14:1637. doi:10.1038/s41467-023-37290-6. PMID: 36964125.
   PubMed Web of Science ®Google Scholar
• Bar-On YM, Flamholz A, Phillips R, Milo R. SARS-CoV-2 (COVID-19) by the numbers. Elife. 2020;9. doi:10.7554/eLife.57309. PMID: 32228860.
   PubMed Web of Science ®Google Scholar
• Li JZ, Aga E, Bosch RJ, Pilkinton M, Kroon E, MacLaren L, Keefer M, Fox L, Barr L, Acosta E, et al. Time to viral rebound after interruption of modern antiretroviral therapies. Clin Infect Dis. 2022;74:865–70. doi:10.1093/cid/ciab541. PMID: 34117753.
   PubMed Web of Science ®Google Scholar
• Boucau J, Uddin R, Marino C, Regan J, Flynn JP, Choudhary MC, Chen G, Stuckwisch AM, Mathews J, Liew MY, et al. Characterization of virologic rebound following nirmatrelvir-ritonavir treatment for COVID-19. Clin Infect Dis. 2022. doi:10.1093/cid/ciac512. PMID: 35737946.
   PubMed Web of Science ®Google Scholar
• Ranganath N, O’Horo JC, Challener DW, Tulledge-Scheitel SM, Pike ML, Michael O’Brien R, Razonable RR, Shah A. Rebound phenomenon after nirmatrelvir/ritonavir treatment of coronavirus disease-2019 in high-risk persons. Clin Infect Dis. 2022. doi:10.1093/cid/ciac481. PMID: 35698452.
   Web of Science ®Google Scholar
• Baum A, Ajithdoss D, Copin R, Zhou A, Lanza K, Negron N, Ni M, Wei Y, Mohammadi K, Musser B, et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Sci. 2020;370:1110–15. doi:10.1126/science.abe2402. PMID: 33037066.
   PubMed Web of Science ®Google Scholar
• Keyt BA, Baliga R, Sinclair AM, Carroll SF, Peterson MS. Structure function, and therapeutic use of IgM antibodies. Antibodies. 2020;9:53. doi:10.3390/antib9040053. PMID.
   Web of Science ®Google Scholar
• Gagnon P, Hensel F, Lee S, Zaidi S. Chromatographic behavior of IgM: dNA complexes. J Chromatogr A. 2011;1218:2405–12. doi:10.1016/j.chroma.2010.12.066. PMID: 21215402.
   PubMed Web of Science ®Google Scholar
• Sama IE, Voors AA, van Veldhuisen DJ. New data on soluble ACE2 in patients with atrial fibrillation reveal potential value for treatment of patients with COVID-19 and cardiovascular disease. Eur Heart J. 2020;41:4047–49. doi:10.1093/eurheartj/ehaa761. PMID: 33118012.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Lindback J, Eriksson N, Hijazi Z, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Yusuf S, Oldgren J, et al. Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. Eur Heart J. 2020;41:4037–46. doi:10.1093/eurheartj/ehaa697. PMID: 32984892.
   PubMed Web of Science ®Google Scholar
• Glasgow A, Glasgow J, Limonta D, Solomon P, Lui I, Zhang Y, Nix MA, Rettko NJ, Zha S, Yamin R, et al. Engineered ACE2 receptor traps potently neutralize SARS-CoV-2. Proc Natl Acad Sci U S A. 2020;117:28046–55. doi:10.1073/pnas.2016093117. PMID: 33093202.
   PubMed Web of Science ®Google Scholar
• Borrok MJ, Luheshi NM, Beyaz N, Davies GC, Legg JW, Wu H, Dall’acqua WF, Tsui P. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcalphaRI (CD89) binding. MAbs. 2015;7:743–51. doi:10.1080/19420862.2015.1047570. PMID: 25970007.
   PubMed Web of Science ®Google Scholar
• Von Kreudenstein TS, Escobar-Carbrera E, Lario PI, D’Angelo I, Brault K, Kelly J, Durocher Y, Baardsnes J, Woods RJ, Xie MH, et al. Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design. MAbs. 2013;5:646–54. doi:10.4161/mabs.25632. PMID: 23924797.
   PubMed Web of Science ®Google Scholar
• Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Xiao J, Hooper AT, Hamilton JD, Musser BJ, et al. REGEN-COV antibody combination and outcomes in outpatients with covid-19. N Engl J Med. 2021;385:e81. doi:10.1056/NEJMoa2108163. PMID: 34587383.
   PubMed Web of Science ®Google Scholar
• Nathan R, Shawa I, De La Torre I, Pustizzi JM, Haustrup N, Patel DR, Huhn G. A narrative review of the clinical practicalities of bamlanivimab and etesevimab antibody therapies for SARS-CoV-2. Infect Dis Ther. 2021;10:1933–47. doi:10.1007/s40121-021-00515-6. PMID: 34374951.
   PubMed Web of Science ®Google Scholar
• Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brunink S, Schneider J, Schmidt ML, et al. Detection of 2019 novel coronavirus (2019-nCov) by real-time RT-PCR. Euro Surveill. 2020;25. doi:10.2807/1560-7917.ES.2020.25.3.2000045. PMID: 31992387.
   Google Scholar
• Akache B, Renner TM, Tran A, Deschatelets L, Dudani R, Harrison BA, Duque D, Haukenfrers J, Rossotti MA, Gaudreault F, et al. Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant. null. 2021;11:21849. doi:10.1038/s41598-021-01363-7. PMID: 34750472.
   Google Scholar